Evaxion announces 2025 milestones reflecting continued strong strategy execution

GlobeNewswire12-09

With most of Evaxion’s strategic milestones for 2024 now successfully achieved, the company announces milestones for 2025 The 2025 key milestones reflect all parts of Evaxion’s strategy for value ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490249267?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/uytrwEfXgkMDzYGWWPzG2g--~B/aD04MTc7dz00NzI1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c9e7552492c4f1a24fb1488cbbdf90ad","is_english":true,"pubTime":"2024-12-09 21:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2490249267","market":"us","top_or_hot":-1,"title":"Evaxion announces 2025 milestones reflecting continued strong strategy execution","media":"GlobeNewswire","content":"<div>\n<p>With most of Evaxion’s strategic milestones for 2024 now successfully achieved, the company announces milestones for 2025\nThe 2025 key milestones reflect all parts of Evaxion’s strategy for value ...</p>\n\n<a href=\"https://finance.yahoo.com/news/evaxion-announces-2025-milestones-reflecting-130000534.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evaxion announces 2025 milestones reflecting continued strong strategy execution</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvaxion announces 2025 milestones reflecting continued strong strategy execution\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-09 21:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/evaxion-announces-2025-milestones-reflecting-130000534.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>With most of Evaxion’s strategic milestones for 2024 now successfully achieved, the company announces milestones for 2025\nThe 2025 key milestones reflect all parts of Evaxion’s strategy for value ...</p>\n\n<a href=\"https://finance.yahoo.com/news/evaxion-announces-2025-milestones-reflecting-130000534.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EVAX","symbol_name":"Evaxion Biotech A/S","start_time":0,"source_url":"https://finance.yahoo.com/news/evaxion-announces-2025-milestones-reflecting-130000534.html","article_id":"2490249267","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/uytrwEfXgkMDzYGWWPzG2g--~B/aD04MTc7dz00NzI1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/c9e7552492c4f1a24fb1488cbbdf90ad"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490249267","pubTimestamp":1733749200,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"With most of Evaxion’s strategic milestones for 2024 now successfully achieved, the company announces milestones for 2025. The 2025 key milestones reflect all parts of Evaxion’s strategy for value realization. Evaxion expects to discuss the milestones at an investor event in the first quarter of 2025. COPENHAGEN, Denmark, December 9, 2024 - Evaxion Biotech A/S  , a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, announces its strategic milestones for 2025 after having now achieved almost all the milestones set for 2024.The 2025 milestones reflect Evaxion’s high activity level, broad pipeline and strong external interest in potential partnerships around both our AI-Immunology platform and pipeline assets. As such, the milestones underscore our continued anticipated strategic progress.All this is reflected in the 2025 milestones as listed below. Evaxion expects to discuss the milestones at an investor event in the first quarter of 2025.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"EVAX":"Evaxion Biotech A/S","WRD":"文远知行","BK4139":"生物科技","PHH":"Park Ha Biological Technology Co. Ltd."},"translate_title":"Evaxion宣布2025年里程碑，反映持续强劲的战略执行","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHH":1,"WRD":1,"EVAX":0.9},"content_text":"With most of Evaxion’s strategic milestones for 2024 now successfully achieved, the company announces milestones for 2025\nThe 2025 key milestones reflect all parts of Evaxion’s strategy for value realization\nEvaxion expects to discuss the milestones at an investor event in the first quarter of 2025\n\nCOPENHAGEN, Denmark, December 9, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces its strategic milestones for 2025 after having now achieved almost all the milestones set for 2024.\nThe 2025 milestones reflect Evaxion’s high activity level, broad pipeline and strong external interest in potential partnerships around both our AI-Immunology™ platform and pipeline assets. As such, the milestones underscore our continued anticipated strategic progress.\n“We have been very successful in executing our strategy and plans throughout 2024. This makes us excited and confident looking into 2025, as reflected in the milestones for the year. In essence, our strategy for value creation is unchanged and so is our daily focus on executing this strategy to the benefit of shareholders, patients and employees,” says Christian Kanstrup, CEO of Evaxion.\nEvaxion’s overriding priorities are execution upon our business development strategy, continuation of the ongoing EVX-01 phase 2 trial, the ongoing strengthening of our AI-Immunology™ platform and further advancement of our research activities, including progressing our ERV-based precision vaccine concept towards clinical development. Finally, the focus is, of course, on advancing our existing partnerships, including bringing the MSD collaboration, entered in September 2024, to option exercise.\nAll this is reflected in the 2025 milestones as listed below. Evaxion expects to discuss the milestones at an investor event in the first quarter of 2025.\n\n\n\n \nMilestones \nTarget \n\n\nAI-Immunology™ \nLaunch of automated lead vaccine candidate design module\nH2\n\n\nBusiness development and partnerships \nAt least two new agreements\n2025\n\n\nEVX-01\nAll patients completed EVX-01 dosing\nH1\n\n\nEVX-01 \nSupplemental phase 2 biomarker and immunogenicity data\nH1\n\n\nEVX-01 \nTwo-year phase 2 clinical efficacy readout\nH2\n\n\nPrecision ERV cancer vaccines \nSelection of lead vaccine candidate\nH2\n\n\nMSD vaccine collaboration (EVX-B2/EVX-B3) \nMSD option exercise, up to USD 10 million option exercise fee\nH2\n\n\nEVX-V1 \nLead antigens selected for CMV vaccine candidate\nH2\n\n\nInfectious diseases \nTwo new pipeline candidates\n1 in H1, 1 in H2\n\n\n\nContact information Evaxion Biotech A/SMads KronborgVice President, Investor Relations & Communication+45 53 54 82 96mak@evaxion-biotech.com \nAbout EVAXION Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.\nForward-looking statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490249267"}